Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer

PURPOSE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been indicated to be an effective treatment for advanced EGFR-mutant NSCLC. However, the neoadjuvant application of EGFR-TKIs in resectable NSCLC needs further investigation. Here, we aimed to evaluate the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Xiaoshun, Dong, Xiaoying, Zhai, Jianxue, Liu, Xiguang, Lu, Di, Ni, Zhen, Wu, Hua, Cai, Kaican
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181135/
https://www.ncbi.nlm.nih.gov/pubmed/34109108
http://dx.doi.org/10.3389/fonc.2021.608608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181135/
https://www.ncbi.nlm.nih.gov/pubmed/34109108
http://dx.doi.org/10.3389/fonc.2021.608608

Ejemplares similares